Post by JHam on Dec 19, 2014 11:16:41 GMT
Wish I could be at this:
oncosec.com/EMAIL_Content/JPM%20IT%20Panel/JMP-Invitation-121814.html
An Introspective on Immunotherapy
A Symposium on Intratumoral Therapy
OncoSec Medical would like to invite you to a special evening with key opinion leaders to discuss the rationale and potential of intratumoral immunotherapy, and OncoSec’s role as a leader in this field.
Join us to learn more from the experts about how intratumoral therapies can generate potent anti-tumor immune responses, while minimizing systemic exposure and side-effects.
Presenters:
Holbrook Kohrt, MD, PhD.
Assistant Professor, Medical Oncology, Stanford University
Scientific Advisory Board Member, OncoSec
Key Opinion Leader in Immunotherapy and Advisor to several pharma companies
Robert Andtbacka, MD
Associate Professor, Surgery, University of Utah
Key Opinion Leader in Intralesional Immunotherapies and Advisor to sevaral pharma companies
Lead investigator for T-VEC and Allovectin-7 Trials
Robert Pierce, MD
Chief Scientific Officer, OncoSec Medical
Formerly, Executive Director at Merck Research Labs
Immunology and anti-PD-1 expert
Mai Le, MD
Chief Medical Officer, OncoSec Medical
Formerly, Medical Director at Calithera and Plexxikon
Tuesday, January 13, 2015 | San Francisco, CA
The Palace Hotel
Twin Peaks South, Second Floor
2 New Montgomery Street
San Francisco,California 94105
Presentations and Panel Discussion (Q&A) | 5:00pm – 6:00pm
Cocktail Reception | 6:00pm – 7:00pm
The success of immunotherapy drugs, like YERVOY (anti-CTLA-4) and KEYTRUDA (anti-PD-1), that activate immune cells to reverse cancer induced immunotolerance has resulted in a paradigm shift in oncology. Evidence is mounting to support the concept that these immune targeting drugs may work by modulating T cells already present in the tumor and immediately adjacent stroma. If these immune cells (TILs) are not present at the tumor site, then these drugs may not be effective. In fact, the lack of TILs constitutes a major – if not the primary – mode of non-response to anti-PD1/PDL1 therapeutic mAbs. Intratumoral therapy with immune=stimulatory molecules like IL-12 offers the promise of re-booting the immune system to drive a TIL response through activation of innate immunity and concomitant exposure to tumor antigens through the induction of immunogenic cell death, so called “in-situ vaccination”. This is an emerging new concept that has the potential to launch cancer immunotherapy into the top of the therapeutic canon for a wide variety of oncology indications.
For more information or to RSVP: jkopin@oncosec.com
oncosec.com/EMAIL_Content/JPM%20IT%20Panel/JMP-Invitation-121814.html
An Introspective on Immunotherapy
A Symposium on Intratumoral Therapy
OncoSec Medical would like to invite you to a special evening with key opinion leaders to discuss the rationale and potential of intratumoral immunotherapy, and OncoSec’s role as a leader in this field.
Join us to learn more from the experts about how intratumoral therapies can generate potent anti-tumor immune responses, while minimizing systemic exposure and side-effects.
Presenters:
Holbrook Kohrt, MD, PhD.
Assistant Professor, Medical Oncology, Stanford University
Scientific Advisory Board Member, OncoSec
Key Opinion Leader in Immunotherapy and Advisor to several pharma companies
Robert Andtbacka, MD
Associate Professor, Surgery, University of Utah
Key Opinion Leader in Intralesional Immunotherapies and Advisor to sevaral pharma companies
Lead investigator for T-VEC and Allovectin-7 Trials
Robert Pierce, MD
Chief Scientific Officer, OncoSec Medical
Formerly, Executive Director at Merck Research Labs
Immunology and anti-PD-1 expert
Mai Le, MD
Chief Medical Officer, OncoSec Medical
Formerly, Medical Director at Calithera and Plexxikon
Tuesday, January 13, 2015 | San Francisco, CA
The Palace Hotel
Twin Peaks South, Second Floor
2 New Montgomery Street
San Francisco,California 94105
Presentations and Panel Discussion (Q&A) | 5:00pm – 6:00pm
Cocktail Reception | 6:00pm – 7:00pm
The success of immunotherapy drugs, like YERVOY (anti-CTLA-4) and KEYTRUDA (anti-PD-1), that activate immune cells to reverse cancer induced immunotolerance has resulted in a paradigm shift in oncology. Evidence is mounting to support the concept that these immune targeting drugs may work by modulating T cells already present in the tumor and immediately adjacent stroma. If these immune cells (TILs) are not present at the tumor site, then these drugs may not be effective. In fact, the lack of TILs constitutes a major – if not the primary – mode of non-response to anti-PD1/PDL1 therapeutic mAbs. Intratumoral therapy with immune=stimulatory molecules like IL-12 offers the promise of re-booting the immune system to drive a TIL response through activation of innate immunity and concomitant exposure to tumor antigens through the induction of immunogenic cell death, so called “in-situ vaccination”. This is an emerging new concept that has the potential to launch cancer immunotherapy into the top of the therapeutic canon for a wide variety of oncology indications.
For more information or to RSVP: jkopin@oncosec.com
The company is pretty confident in what they have going for them and they want people to know about it. The last paragraph in this PR says it all. Paraphrasing; A lack of TILs is the reason why anti-PD1 drugs don't get a great response rate, but IL-12 will change that.